NCT03636503 2025-02-06
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
Dana-Farber Cancer Institute
EMD Serono
EMD Serono
Kyowa Kirin Co., Ltd.
Leap Therapeutics, Inc.
Fate Therapeutics
Fate Therapeutics
Washington University School of Medicine